What did @mccallmcphersonpa actually say?
The core claim here is straightforward: low testosterone puts you at "a 24% increased risk of cardiovascular disease." The follow-up logic is that restoring testosterone to optimal levels will "likely" reduce that risk. The creator also references VA studies with 150,000 people, ties low testosterone to all-cause mortality, bone density, and then floats a connection between testosterone deficiency and Alzheimer's-related tau protein accumulation. To their credit, they explicitly disclaim that testosterone is not indicated for cancer or Alzheimer's treatment today.
The framing is optimistic and clinic-forward, which makes sense given the platform. But optimistic framing and accurate framing are not always the same thing, and the 24% figure and the cardiovascular reversal logic deserve a closer look.
Does the science back this up?
The 24% figure is real, but it comes with significant context the video skips. The association between low testosterone and cardiovascular disease risk is documented, but the causal direction is genuinely contested.
A 2011 meta-analysis by Ruige et al. in the European Heart Journal found that low endogenous testosterone was associated with increased cardiovascular mortality, and pooled estimates in similar analyses have landed in the 20-25% relative risk range. The VA study referenced is almost certainly Shores et al. (2006, Archives of Internal Medicine), which looked at 858 men with low testosterone and found increased mortality, not the 150,000-person figure cited, which may be conflating multiple datasets.
The bigger problem is the reversal claim. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine), the largest randomized controlled trial of testosterone therapy in men with hypogonadism to date, found that testosterone replacement was non-inferior to placebo for major adverse cardiovascular events. That is good news for safety, but it is not the same as saying TRT reduces cardiovascular risk. The video implies a cleaner causal story than the evidence currently supports.
What did they get wrong (or right)?
They got the association right. Low testosterone is consistently linked to worse cardiovascular outcomes in observational data. That 24% figure is defensible as a ballpark from meta-analytic data, even if the specific sourcing is vague.
What they got wrong is the leap. Saying "by function of that" restoring testosterone will "likely" reduce cardiovascular disease risk is a classic conflation of association with intervention benefit. Epidemiological associations do not automatically reverse with treatment. Blood pressure associations taught us this. Cholesterol associations taught us this. Testosterone is no different until the RCT data says otherwise.
The tau protein and Alzheimer's claim is the weakest part of the segment. There is early mechanistic research, including work by Tan and Craft (reviewed in Frontiers in Aging Neuroscience, 2022), suggesting testosterone may influence amyloid and tau pathways. But calling this "data that shows testosterone deficiency is implicated in the increase of these proteins" is doing a lot of heavy lifting on preliminary findings. The creator does issue a disclaimer here, which is appropriate. The problem is the disclaimer comes after the implication has already landed.
What should you actually know?
If you have clinically confirmed hypogonadism, the cardiovascular safety profile of TRT has improved substantially with the TRAVERSE trial data. That matters. Men with low testosterone who were previously scared away from treatment due to older, flawed studies (the 2010 Basaria et al. NEJM trial, for instance, which was stopped early and has been widely criticized) now have stronger reassurance on safety.
What TRT is not, based on current evidence, is a proven cardiovascular protective intervention. It may be metabolically beneficial in some populations, particularly men with obesity-related secondary hypogonadism, but prescribing testosterone specifically to reduce heart attack risk is not supported by current guidelines from the American Urological Association or the Endocrine Society.
The Alzheimer's angle is genuinely interesting science that is years away from clinical application. Anyone presenting it as a near-term treatment rationale is getting ahead of the data. If you are curious about testosterone and your health, talk to a physician who will actually measure your levels rather than one who starts with the conclusion.